Hepatitis C Virus Infection Influences the S-Methadone Metabolite Plasma Concentration
Open Access
- 23 July 2013
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (7) , e69310
Abstract
Heroin-dependent patients typically contract hepatitis C virus (HCV) at a disproportionately high level due to needle exchange. The liver is the primary target organ of HCV infection and also the main organ responsible for drug metabolism. Methadone maintenance treatment (MMT) is a major treatment regimen for opioid dependence. HCV infection may affect methadone metabolism but this has rarely been studied. In our current study, we aimed to test the hypothesis that HCV may influence the methadone dosage and its plasma metabolite concentrations in a MMT cohort from Taiwan. A total of 366 MMT patients were recruited. The levels of plasma hepatitis B virus (HBV), HCV, human immunodeficiency virus (HIV) antibodies (Ab), liver aspartate aminotransferase (AST) and alanine aminotransferase (ALT), as well as methadone and its metabolite 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP) were measured along with the urine morphine concentration and amphetamine screening. Of the 352 subjects in our cohort with HCV test records, 95% were found to be positive for plasma anti-HCV antibody. The liver functional parameters of AST (Wilcoxon Rank-Sum test, P = 0.02) and ALT (Wilcoxon Rank-Sum test, P = 0.04), the plasma methadone concentrations (Wilcoxon Rank-Sum test, P = 0.043) and the R-enantiomer of methadone concentrations (Wilcoxon Rank-Sum test, P = 0.032) were significantly higher in the HCV antibody-positive subjects than in the HCV antibody-negative patients, but not the S-EDDP/methadone dose ratio. The HCV levels correlated with the methadone dose ( = 14.65 and 14.13; P = 0.029 and 0.03) and the S-EDDP/methadone dose ratio ( = −0.41 and −0.40; P = 0.00084 and 0.002) in both univariate and multivariate regression analyses. We conclude that HCV may influence the methadone dose and plasma S-EDDP/methadone dose ratio in MMT patients in this preliminary study.Keywords
This publication has 47 references indexed in Scilit:
- Genetic polymorphisms in the opioid receptor mu1 gene are associated with changes in libido and insomnia in methadone maintenance patientsEuropean Neuropsychopharmacology, 2012
- HCV and HIV Infection among Heroin Addicts in Methadone Maintenance Treatment (MMT) and Not in MMT in Changsha and Wuhan, ChinaPLOS ONE, 2012
- High Prevalence of HIV, HCV, HBV and Co-Infection and Associated Risk Factors among Injecting Drug Users in Yunnan Province, ChinaPLOS ONE, 2012
- Serum IL-33 Levels Are Associated with Liver Damage in Patients with Chronic Hepatitis CMediators of Inflammation, 2012
- Noninvasive assessment of hepatic fibrosis in Egyptian patients with chronic hepatitis C virus infectionWorld Journal of Gastroenterology, 2012
- A comparison of four fibrosis indexes in chronic HCV: Development of new fibrosis-cirrhosis index (FCI)BMC Gastroenterology, 2011
- Hepatitis C testing and treatment among active drug users in AmsterdamEuropean Journal of Gastroenterology & Hepatology, 2011
- When and how to evaluate mildly elevated liver enzymes in apparently healthy patientsCleveland Clinic Journal of Medicine, 2010
- Direct Subunit-Dependent Multimodal 5-Hydroxytryptamine3 Receptor Antagonism by MethadoneMolecular Pharmacology, 2009
- L-Methadone and D,L-Methadonein Methadone Maintenance Treatment: A Comparison of Therapeutic Effectiveness and Plasma ConcentrationsEuropean Addiction Research, 1998